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Abstract
Background: The objective of this study is the evaluation of the Masaoka-Koga and the International Association
for the Study of Lung Cancer (IASLC)/International Thymic Malignancy Interest Group (ITMIG) proposal for the new
TNM-staging system on clinical implementation and prognosis of thymic malignancies.
Methods: A retrospective study of 76 patients who underwent surgery between January 2005 and December 2015
for thymoma. Kaplan–Meier survival analysis was used to determine overall and recurrence-free survival rates.
Results: Indication for surgery was primary mediastinal tumor (n = 55), pleural manifestation (n = 17), or mediastinal
recurrence (n = 4) after surgery for thymoma. Early Masaoka-Koga stages I (n = 9) and II (n = 14) shifted to the new
stage I (n = 23). Advanced stages III (Masaoka-Koga: n = 20; ITMIG/IASLC: n = 17) and IV (Masaoka-Koga: n = 33;
ITMIG/IASLC: n = 35) remained nearly similar and were associated with higher levels of WHO stages. Within each
staging system, the survival curves differed significantly with the best 5-year survival in early stages I and II (91%).
Survival for stage IV (70 to 77%) was significantly better compared to stage III (49 to 54%). Early stages had a
significant longer recurrence-free survival (86 to 90%) than advanced stages III and IV (55 to 56%).
Conclusions: The proportion of patients with IASLC/ITMIG stage I increased remarkably, whereas the distribution in
advanced stages III and IV was nearly similar. The new TNM-staging system presents a clinically useful and
applicable system, which can be used for indication, stage-adapted therapy, and prediction of prognosis for overall
and recurrence-free survival.
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Background
Main objective of therapy in all stages of thymoma and
thymic carcinoma should be complete surgical resection
based on a stage-adapted treatment including multimodal-
ity therapy in advanced stages [1–3]. Prognosis depends
on the preoperative tumor stage mainly characterized by
the anatomical extend (Masaoka-Koga classification), the
World Health Organization (WHO) histological classi-
fication system, and the completeness of surgical re-
section [4–8]. At least 15 different stage classification
systems for thymic tumors have been proposed and
implemented in the last decades [9]. However, the
Masaoka-Koga classification remains the most common
and frequently applied clinical staging system [10].
Recently, the International Association for the Study
of Lung Cancer (IASLC) and the International Thymic
Malignancy Interest Group (ITMIG) have proposed a
new classification for thymic malignancies [11, 12]. The
IACLC/ITMIG staging system has now been approved
by the Union for the International Cancer Control (UICC)
and the American Joint Committee on Cancer (AJCC) in
the eight edition of the TNM classification [13, 14].
Objective of this study was the evaluation of patients
with thymoma or thymic carcinoma who underwent
surgical resection and to compare their characteristics,
indications for surgery, and outcomes when classified ac-
cording to the Masaoka-Koga system and with the new
proposed IASLC/ITMIG TNM-staging system.
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Methods
Study design
This was a retrospective, non-randomized study at the
Department of Thoracic Surgery, University Medical
Center Regensburg, and the Department of Thoracic
Surgery, Hospital Barmherzige Brüder Regensburg. Be-
tween January 2005 and December 2015, a total of 76
consecutive patients with thymoma or thymic carcin-
oma, who underwent radical surgical resection, were
included.
The study was approved by our Institutional Review
Board, which waived the requirement for an individual
patient consent because only routine patient data were
used for this retrospective analysis. Patient characteris-
tics and operative reports were obtained from the insti-
tutional database and medical records. Preoperative
staging included contrast-enhanced computed tomog-
raphy (CT) scan of the chest in all patients. The pre-
operative clinical and pathologic stage was determined
according to Masaoka-Koga staging system [7]. The
pathologic results were classified according to the WHO
histological classification system [14, 15]. The proposed
IASLC/ITMIG stages were determined, using the pre-
operative imaging in addition to histological, surgical,
and medical reports.
Induction therapy was administered in patients with ad-
vanced tumor stages, which were considered not completely
resectable and in order to increase the chance for complete
resection. Adjuvant therapies including chemotherapy or
radiotherapy were accomplished depending on tumor stage,
histology, completeness of resection, and the postoperative
patient’s status [3]. A further reason for not performing
adjuvant therapy was patient refusal.
During the study period, eight patients with recurrence
of thymoma underwent surgical resection again without
any complication and with a macroscopic complete tumor
resection (mediastinal or lung: R0; pleural: R0/R1).
Proposed IASCL/ITMIG staging system
The proposed IASLC/ITMIG staging system was first
published 2014 and is a new evidence-based TNM-staging
system for thymic malignancies according to the TNM
classification of the UICC of malignant tumors (Table 1)
[11, 13, 14]. The greatest significance has the T descriptor,
which evaluates the local tumor invasion, whereas nodal
or distant metastases are uncommon [16]. It describes the
invasion into mediastinal fat (T1a), mediastinal pleura
(T1b), pericardium (T2), and other surrounding structures
or organs (T3, T4) [17]. The N descriptor distinguishes
between involvement of N1 (anterior/perithymic) and N2
(deep intrathoracic/cervical) lymph nodes [18]. The M de-
scriptor indicates whether pleural and pericardial nodules
(M1a) or distant organ metastases (M1b), including pul-
monary intraparenchymal metastases, are evident [19].
Follow-up
Overall survival and recurrence-free survival were calcu-
lated from the date of surgery. Follow-up analysis was
Table 1 Stages of thymic tumors according to Masaoka-Koga classification and the proposed IASLC/ITMIG classification [5, 7, 13]
Stage Masaoka-Koga IASCL/ITMIG
I Completely encapsulated tumor
Invasion into but not through the capsule
T1N0M0
T1a: Encapsulated or extending into the anterior mediastinal fat
T1b: Direct involvement of the mediastinal pleura
II (a) Microscopic transcapsular invasion
(b) Macroscopic invasion into thymic or surrounding fatty tissue
Grossly adherent to but not breaking through mediastinal pleura
or pericardium
T2N0M0
T2: Invasion to the pericardium
III Invasion into neighboring organ including
- Mediastinal pleura
- Pericardium
- Visceral pleura or lung
- Phrenic or vagus nerve
- Major vessels
Adherence of lung or adjacent organs
(a) T3N0M0
T3: Invasion to
- Lung
- Brachiocephalic vein
- Superior vena cava
- Chest wall
- Phrenic nerve
(b) T4N0M0
T4: Invasion to
- Aorta
- Intrapericardial pulmonary artery
- Myocardium
- Trachea
- Esophagus
IV (a) Pleural or pericardial metastases
(b) Any nodal involvement and distant metastases
(a) TanyN1M0, TanyN0M1a
N1: Anterior (perithymic) nodes
M1a: Separate pleural or pericardial nodule
(b) N2 and/or M1b
N2: Deep intrathoracic or cervical nodes
M1b: Pulmonary intraparenchymal nodule or distant organ metastasis
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conducted until either death or at the end of March
2016 in order to document tumor recurrence and the
patients’ overall survival.
Statistical analysis
Statistical analysis was performed with SPSS 16.0 (SPSS
Inc., Chicago, IL) for Windows (Microsoft Corp, Redmond,
WA). Descriptive statistics were used to describe patient
characteristics and to compare variables. Categorical data
are shown as frequency distributions (n) and percentages
(%). The Kaplan–Meier method was used to plot survival
curves, and the log-rank test was used to evaluate differ-
ences between subgroups. To perform the statistical evalu-
ation of the two staging systems, we estimated the hazard
ratio for each group in the two systems using the Cox
regression analysis. Differences with a p value of < 0.05
were considered to be statistically significant.
Results
Patient characteristics
Patient characteristics are listed in Table 2. The study
comprised a total of 76 patients (53.9% male) with evi-
dence of thymoma or thymic carcinoma, which was first
identified as a primary mediastinal tumor (n = 55; 72.4%),
pleural manifestation (n = 17; 22.4%), or as a suspected me-
diastinal recurrence (n = 4; 5.2%) after resection of a malig-
nant thymic tumor before the study period. Patients with
advanced tumor stages (Masaoka-Koga stages III and IV)
received frequently preoperative medicamentous treat-
ment (n = 33; 43.4%) with induction chemotherapy
(n = 28; 36.8%) or octreotid/prednisone (n = 5; 6.6%).
Operative data
Details of the surgical procedures and postoperative data
are listed in Table 3. In all patients, a radical tumor resec-
tion including the en bloc resection of the thymoma, along
with the thymic gland, perithymic fat tissue, mediastinal
pleura (n = 44; 57.9%), and pericardium (n = 33; 46.1%),
was performed. When appropriate, the resection was
extended to the lung (n = 32; 42.1%) or the diaphragm
(n = 17; 22.4%). In patients with pleural tumor spread
(Masaoka-Koga stage IVa: n = 28), tumor resection was
achieved by pleurectomy/decortication (P/D: n = 12),
extended P/D (n = 10), extrapleural pneumonectomy
(EPP: n = 3), or localized pleural tumor resection (n = 3).
An additional hyperthermic intrathoracic chemotherapy
Table 2 Patient characteristics
Variable n = 76
(100%)
Gender
Male 41 (53.9)
Female 35 (46.1)
Age (mean; ±SD) [years] 52.6 (± 14.3)
Myasthenia gravis 39 (51.3)
Type of tumor
Primary mediastinal tumor 55 (72.4)
Pleural tumor spread 17 (22.4)
Mediastinal recurrence 4 (5.2)
WHO classification
A 2 (2.6)
AB 5 (6.6)
B1 5 (6.6)
B2 28 (36.8)
Mixed B2/B3 8 (10.5)
B3 18 (23.7)
C (thymus carcinoma) 10 (13.2)
Preoperative treatment
None 43 (56.6)
Induction chemotherapy 28 (36.8)
Octreotid/prednisone 5 (6.6)
Radiotherapy 0 (0)
SD standard deviation, WHO World Health Organization
Table 3 Operative and postoperative data
Variable n = 76
(100%)
Surgery
One approach 41 (53.9)
Two approaches 35 (46.1)
Surgical procedure
Radical thymectomy 61 (18.3)
P/D 12 (15.8)
eP/D 10 (13.2)
EPP 3 (3.9)
HITHOC 19 (25)
Completeness of resection
R0 37 (48.7)
R1 28 (36.8)
R2 11 (14.5)
Complications
Intraoperative 3 (3.9)
Postoperative 10 (13.2)
Adjuvant treatment
Chemotherapy 22 (28.9)
Radiotherapy 19 (25)
30-day mortality 0 (0)
eP/D extended pleurectomy/decortication, EPP extrapleural pneumonectomy,
HITHOC hyperthermic intrathoracic chemotherapy, P/D pleurectomy/
decortication, R0 no residual tumor, R1 microscopic residual tumor, R2
macroscopic residual tumor
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(HITHOC) with cisplatin was done in n = 19 patients
(68%). A complete tumor resection (R0) was achieved in
48.7% of patients. A microscopic (R1: n = 28; 36.8%) or
macroscopic (n = 11; 14.5%) incomplete tumor resection
was documented in advanced stages III (n = 12) and IV
(n = 26), due to tumor infiltration of adjacent structures
or diffuse pleural manifestation. Only one stage II tumor
had a R1 situation, which was treated with adjuvant
radiotherapy.
Stage distribution
Stage distribution according to the Masaoka-Koga sta-
ging system and the proposed TNM-staging system is
based on the pathological results and shown in Table 4.
When comparing both classifications, Masaoka-Koga
stage I patients (n = 9) increased to IASLC/ITMIG stage
I patients (n = 23), and all Masaoka-Koga stage II pa-
tients (n = 14) decreased to n = 1 IASLC/ITMIG stage II
patient. One patient with infiltration of the pericardium
(Masaoka-Koga stage III) is now classified as IASLC/
ITMIG stage II patient. The proportion of patients with
advanced tumor stages III and IV was nearly similar
between both classifications. The stage distribution of
the new system in relation to the WHO classification is
presented in Table 5. Advanced tumor stages are associ-
ated with higher levels of WHO stages (B2 to C).
Survival analysis
Overall 5-year survival rate of all patients was 73%. Be-
cause of the small sample size if distributed in all stages,
early stages I and II were joint together (n = 23) and
compared to advanced stage III (n = 20) or stage IV
(n = 33). Overall survival curves of the three subgroups
according to both staging systems are displayed in Fig. 1.
Within each staging system, the survival curves differed
significantly. A better survival for stage IV (Masaoka-
Koga 77%; IASLC/ITMIG 70%) compared to stage III
(Masaoka-Koga 49%; IASLC/ITMIG 54%) was observed.
Overall 5-year recurrence-free survival was 66% irre-
spective of stage. Early stages had a significant longer
recurrence-free survival (Masaoka-Koga 90%, p = 0.007;
IASLC/ITMIG 86%, p = 0.019) than advanced stages III
and IV (55 to 56%), which were nearly similar (Fig. 2).
All patients with stage IVa tumors due to pleural
spread received multimodality therapy and reached a 5-
year survival rate up to 79%. No significant differences
in survival were documented between primary and sec-
ondary (recurrence) stage IVa (p = 0.616).
The hazard ratios for all stages and subgroups for both
staging systems using the Cox regression analysis are
listed in Table 6. Overall survival in patients with
Masaoka-Koga stage III (p = 0.02) or IASLC/ITMIG
stage IIIa/IIIb (p = 0.03) was significantly declined.
Multivariate analysis was performed including stage, re-
section status, and histology and showed that only the
classification according to IASCL/ITMIG significantly
(p = 0.03) influenced the overall survival.
Discussion
The tumor–node–metastasis (TNM) classification of can-
cers proposed by the UICC is used worldwide and ac-
cepted as a uniform classification system. It provides a
stage-adapted indication system for therapy and helps to
estimate patients’ prognosis [14]. Recently, there is a pro-
posed TNM-staging system, which should be applicable to
all types of thymic malignancies. This new system is based
on a large collaborative amount of 10.808 patient data
available from the ITMIG/IASLC retrospective database,
leaving 8.145 of patients for final analysis. Surgery was
included in 99% of these cases [11, 17].
In our study sample, the proportion of patients with
the proposed IASLC/ITMIG stage I increased remark-
ably because they were reclassified from Masaoka-Koga
stage IIa and IIb diseases. However, this changing in
distribution of early-stage thymoma had no impact on
indication for radical surgery.
The Masaoka-Koga stage III is heterogenous, because
it includes invasion of the mediastinal pleura (T1b), peri-
cardium (T2), and other surrounding structures (T3, T4)
Table 4 Patient distribution (n) between proposed IASLC/ITMIG
stages and Masaoka-Koga classification
IASLC/ITMIG stages Total
I II IIIa IIIb IVa IVb
Masaoka-Koga I 9 0 0 0 0 0 9
IIa 6 0 0 0 0 0 6
IIb 8 0 0 0 0 0 8
III 0 1 15 2 2 0 20
IVa 0 0 0 0 28 0 28
IVb 0 0 0 0 0 5 5
Total 23 1 15 2 30 5 76
Table 5 Patient distribution (n) between proposed IASLC/ITMIG
stages and WHO classification
IASLC/ITMIG stages Total
I II IIIa IIIb IVa IVb
WHO A 2 0 0 0 0 0 2
AB 4 0 0 0 1 0 5
B1 2 0 1 0 2 0 5
B2 9 1 6 0 10 2 28
Mixed B2/B3 1 0 3 0 4 0 8
B3 4 0 3 2 9 0 18
C 1 0 2 0 4 3 10
Total 23 1 15 2 30 5 76
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[20]. In the new proposed system, stage III is divided in
more or most resectable stage IIIa and less or unresect-
able stage IIIb tumors [17]. According to that, both pa-
tients with stage IIIb in this study had invasion of the
aorta or the supraaortic branches and should be consid-
ered only individually for surgical resection, since the
risk of R2 resection is high [21]. Therefore, the TNM
system better characterizes this heterogenous stage III
and supports the indication for surgery or not surgery.
Nevertheless, worst survival was registered in patients
with Masaoka-Koga stage III or proposed stage IIIa/IIIb
thymic tumors.
Especially in patients with advanced thymoma not
eligible for immediate resection, induction therapy is
recommended [22]. Surgical resection should be part of a
multimodality therapy including chemotherapy and in
some cases adjuvant radiotherapy to decrease the risk of
recurrence and improve survival [23, 24]. These neo-
adjuvant treatment indications were not influenced by the
new TNM-staging system.
Furthermore, the new TNM-staging proposal also pro-
vides information on lymphatic involvement and tumor
dissemination [13, 18]. Since the significance of the
lymph node dissection and its impact on adjuvant
Fig. 1 The number of patients in each subgroup is presented as well as the 5-year survival rate [%]. a Significant differences in survival were
documented with respect to three groups of Masaoka-Koga stages. Stage III patients had a lower survival than patients with stage IV. b Survival
curves with respect to the proposed IASLC/ITMIG stages showed also significant differences
Fig. 2 Recurrence-free survival curves for patient subgroups according to the three stage groupings. There were significant differences between
stage I + II compared to stage III or stage IV with respect to the Masaoka-Koga (a) and the proposed IASLC/ITMIG (b) staging system. Recurrence-
free survival was nearly similar between stage III and stage IV
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therapy are still not clear, the imperative for a radical
lymph node dissection remains questionable [16, 25]. So,
most of all do not routinely perform a systematic lymph
node dissection in all patients with thymoma and only
suspicious nodes were resected for histological investiga-
tion. Therefore, we have problems with defining accur-
ately the lymph node status [26].
The changing within early stages did not negatively
affect the 5-year survival rate of 91%, because both early
stages I and II include tumors, which should be com-
pletely resectable, even if they show invasion of the peri-
thymic fat tissue, the mediastinal pleura, or the
pericardium. Less imbalance of stage distribution was
found in advanced stages III and IV. These results are
also in line with the literature [27].
Both, overall survival and recurrence-free survival
were significantly influenced by the three stage group-
ings in early (I + II), advanced (III), and metastatic (IV)
stages. In contrast, a recent study showed only a signifi-
cant deterioration regarding the recurrence-free survival
and not the overall survival [27]. Overall 5-year survival
of 73% and recurrence-free survival of 66% for all
patients in this study group was encouraging, although
approximately 69% of patients had advanced stages III
and IV thymoma/thymic carcinoma.
The survival curves in both staging systems showed a
significant deterioration of prognosis as the stage in-
creased up to stage III. In contrast, stage IV patients
with pleural or lymphatic tumor spread had a significant
better overall survival than patients in stage III. This
survival benefit might be explained, because almost all
our patients in Masaoka-Koga stage IVa underwent suc-
cessful radical surgical resection, which was also com-
bined with the HITHOC (68%) within the last years
[28]. Finally, surgical resection within a multimodality
treatment concept in patients with pleural tumor dis-
semination is feasible and leads to encouraging 5-year
survival rates up to 79%. This multimodality treatment
regime might not be performed in all patients of the col-
laborative IASLC/ITMIG database and therefore was not
taken into account for the final analysis. In addition,
advanced stages were probably underrepresented com-
pared to earlier stage tumors [13].
The recurrence-free survival was nearly similar be-
tween stage III and IV tumors. That means the
biological behavior (e.g., recurrence) of the tumor
seems not to be influenced by the tumor stage. But
the consequence of tumor recurrence seems to be
different in both stages, since mediastinal recurrence
after stage III tumors often directly involves vitally
important structures (i.e., great vessels, heart). On
the other hand, pleural recurrences usually do not
affect vital organs and therefore can often be treated
again surgically, which leads to a prolonged survival.
These patients might benefit from multimodal treat-
ment including surgery and should be evaluated
interdisciplinary [3, 29–31].
Conclusion
In conclusion, the new TNM-staging system presents a
clinically useful and applicable system, which can be used
for indication and stage-adapted therapy. It also seems to
serve as a potential prognostic prediction model for over-
all and recurrence-free survival. Advanced stage IVa pa-
tients can be treated with multimodality therapy including
radical surgery, which results in a longer survival com-
pared to patients with stage III. Systematic lymph node
dissection is recommended and has a strong impact on
stage distribution (stage IV). We all should perform
systematic lymph node dissection, although its impact on
adjuvant therapy and prognosis is still controversial. Fur-
ther studies using prospectively collected data (especially
advanced stages and lymph node status) of large patient
cohorts on the proposed TNM-staging system are war-
ranted to prove our results and would be helpful for
uniform classification of thymic tumors, stage-adapted
therapy, and prediction of prognosis.
Strengths and limitations
We are aware of the potential restrictions of our
study. The obvious limitation is its retrospective, non-
randomized nature. All data were revalidated by an-
other coauthor before analysis. This procedure should
have reduced errors, but did not eliminate them com-
pletely. In particular, the sample size is limited. How-
ever, we present a cohort of surgical patients with a
high percentage of advanced stages, who were treated
within a multimodality therapy regime. We have a
complete follow-up of all patients; thus, the follow-up
period might be relatively short for thymoma, because
of the slow progression and late recurrence of this
tumor entity.
Table 6 Comparison of hazard ratios between Masaoka-Koga
and proposed IASLC/ITMIG stages using Cox’s regression
analysis
Overall survival Recurrence-free survival
HR 95% CI p value HR 95% CI p value
Masaoka-Koga
I + II 1.00 0.054 1.00 0.03
III 6.38 1.38–29.59 0.02 5.79 1.19–28.01 0.03
IVa + IVb 3.64 0.75–17.67 0.11 8.1 1.78–36.79 0.007
IASLC/ITMIG
I + II 1.00 0.09 1.00 0.04
IIIa + IIIb 5.71 1.19–27.49 0.03 3.66 0.91–14.67 0.07
IVa + IVb 4.73 1.01–22.1 0.048 5.31 1.47–19.15 0.01
CI confidence interval, HR hazard ratio
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